2:21 PM
 | 
Apr 20, 2018
 |  BC Extra  |  Company News

Brazil nixes Soliris patent, says more could follow

A Brazilian court unanimously ruled Friday to remove patent protection for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), opening the door for production of biosimilar versions in the country. In a statement, Brazil’s Attorney General Office said Soliris is only the first of "several other drugs" it plans to challenge in court.

Alexion markets Soliris...

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >